#USA #Novavax #Gaithersburg #Pfizer #Matrix-M

Novavax Unveils Strong Financial Performance for 2025

On February 26, 2026, Novavax, Inc. (NASDAQ: NVAX) reported its financial results for the fourth quarter and the entirety of 2025. The report highlighted significant growth in revenue and key operational milestones, driven largely by strategic partnerships, notably with Pfizer and Sanofi.

Financial Highlights

In the fourth quarter of 2025, Novavax achieved total revenues of $147 million, reflecting a substantial 67% increase from $88 million during the same period in 2024. For the entire year of 2025, the company posted total revenues of $1.1 billion, a noteworthy 65% rise compared to $682 million in 2024. This growth can be largely attributed to the successful commercialization of its COVID-19 vaccine, Nuvaxovid™, and proactive business strategies, including revenue share agreements with major pharmaceutical players.

The increase in revenue included approximately $625 million from Nuvaxovid, primarily stemming from Advance Purchase Agreements negotiated in prior years,
indicating strong demand for the vaccine. Interestingly, Novavax reported a net income of $18 million in Q4 2025, a reversal from a loss of $81 million in Q4 2024. For the full year, the net income was $440 million versus a net loss of $187 million in 2024. This marked improvement highlights the effectiveness of Novavax's cost-reduction measures and operational efficiencies.

Strategic Partnerships

One of the most notable operational advancements was the partnership with Pfizer, which was established in January 2026. Under the new agreement, Pfizer obtained a non-exclusive license to utilize Novavax's Matrix-M® adjuvant technology for developing vaccines targeting two infectious disease areas. For this arrangement, Novavax received a $30 million upfront payment, with the potential of earning up to $500 million through further development and sales milestones. The partnership is expected to significantly bolster Novavax’s revenue streams in the coming years, as Pfizer takes on the responsibility for the associated product development and commercialization.

Additionally, Novavax continued to build on its successful collaboration with Sanofi, earning $225 million in milestone payments from this partnership throughout 2025. This collaboration facilitated the progress of combination vaccines against influenza and COVID-19, with a strong likelihood of demonstrating competitive efficacy in upcoming Phase 3 trials,
according to reports from Sanofi.

The company also entered several Material Transfer Agreements (MTAs) aimed at exploring the efficacy of Matrix-M in upcoming vaccine developments with various global pharmaceutical partners. Such collaborations further validate Novavax's innovative capabilities while expanding its market reach.

Advancements in Research and Development

Beyond financial aspects, Novavax is making strides in its research and development pipeline. Preclinical research on vaccine candidates targeting infections such as Clostridioides difficile and varicella-zoster virus is ongoing, with expectations to enter human trials by as early as 2027. These developmental efforts are crucial for sustaining Novavax's competitive edge in the biotech sector, as they aim to leverage their proprietary Matrix-M technology in various therapeutic areas, including oncology.

Cost Management and Future Outlook

Novavax also reported notable success in managing its operational costs. The company met or exceeded its research and development (R&D) and selling, general, and administrative (SGA) expense reduction targets for 2025, aiming for non-GAAP expenses to be significantly lower than in previous years. For the fiscal years 2026 through 2028, Novavax has set ambitious yet achievable goals for further cost reductions, targeting approximately $325 million in 2026 and steadily decreasing from there.

With a cash reserve of $751 million as of December 31, 2025, and a new $330 million credit facility to support ongoing operations, Novavax is well-positioned to navigate future developments. The comprehensive financial and operational results indicate a promising trajectory for the company, underscoring its commitment to driving vaccine innovation and expanding its impact on global health.

In conclusion, as Novavax embarks on new projects and ventures in 2026, its recent achievements in partnerships, revenue growth, and R&D progress lay a solid foundation for future success. The company’s ongoing strategies to optimize costs while expanding its technology reach will be closely monitored by investors and industry experts alike.